IRIS UniCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.097
AS - Asia 9.492
EU - Europa 8.925
SA - Sud America 1.844
Continente sconosciuto - Info sul continente non disponibili 406
AF - Africa 258
OC - Oceania 21
Totale 33.043
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.596
SG - Singapore 4.498
DE - Germania 2.150
IT - Italia 2.114
CN - Cina 2.062
BR - Brasile 1.467
SE - Svezia 888
NL - Olanda 869
VN - Vietnam 830
FR - Francia 774
GB - Regno Unito 434
IE - Irlanda 394
IN - India 325
ID - Indonesia 278
JP - Giappone 278
HK - Hong Kong 245
CA - Canada 234
FI - Finlandia 230
UA - Ucraina 223
RU - Federazione Russa 219
BD - Bangladesh 201
PL - Polonia 147
KR - Corea 138
AR - Argentina 136
MX - Messico 132
TR - Turchia 125
ES - Italia 97
IQ - Iraq 97
ZA - Sudafrica 78
AT - Austria 65
EC - Ecuador 62
CO - Colombia 59
PK - Pakistan 57
BE - Belgio 48
SA - Arabia Saudita 48
CH - Svizzera 42
VE - Venezuela 39
IR - Iran 38
CZ - Repubblica Ceca 37
LT - Lituania 36
PH - Filippine 29
AE - Emirati Arabi Uniti 28
MA - Marocco 28
UZ - Uzbekistan 27
CI - Costa d'Avorio 26
EG - Egitto 26
JM - Giamaica 25
KE - Kenya 24
PA - Panama 24
CL - Cile 23
IL - Israele 22
JO - Giordania 22
PY - Paraguay 22
CR - Costa Rica 21
RO - Romania 20
TN - Tunisia 19
RS - Serbia 18
OM - Oman 15
TH - Thailandia 15
PE - Perù 14
BG - Bulgaria 13
MK - Macedonia 13
MY - Malesia 13
TT - Trinidad e Tobago 13
UY - Uruguay 13
KZ - Kazakistan 12
NP - Nepal 12
PT - Portogallo 12
AU - Australia 11
DK - Danimarca 11
DZ - Algeria 11
AL - Albania 10
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
HN - Honduras 10
NG - Nigeria 10
KG - Kirghizistan 9
BY - Bielorussia 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
AM - Armenia 7
GR - Grecia 7
HU - Ungheria 7
TW - Taiwan 7
BO - Bolivia 6
ET - Etiopia 6
GT - Guatemala 6
HR - Croazia 6
LB - Libano 6
LK - Sri Lanka 6
SN - Senegal 6
GE - Georgia 5
LV - Lettonia 5
BH - Bahrain 4
QA - Qatar 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
Totale 32.565
Salva come PNG Salva come JPEG
Città #
Singapore 2.673
Ashburn 1.358
San Jose 1.348
Chandler 1.008
Amsterdam 716
New York 466
Los Angeles 416
Rome 398
Hefei 390
Beijing 367
Dublin 359
Ho Chi Minh City 297
Milan 288
Frankfurt am Main 270
Tokyo 260
Jakarta 248
Lauterbourg 235
Hong Kong 220
Hanoi 201
Dallas 190
Munich 178
São Paulo 155
San Mateo 150
Boston 137
Seoul 132
Chicago 130
Santa Clara 130
Jacksonville 126
Tukwila 126
Moscow 123
Helsinki 113
Marseille 111
Kent 110
Houston 103
Buffalo 100
Nanjing 100
Warsaw 99
Wilmington 98
Atlanta 97
Nürnberg 91
The Dalles 91
Boardman 79
Dearborn 79
Princeton 79
Orem 78
Brooklyn 75
Council Bluffs 75
Montreal 75
London 73
Phoenix 73
Ann Arbor 70
Nuremberg 70
Woodbridge 68
Seattle 63
Denver 62
Paris 62
Chennai 59
Stockholm 54
Toronto 54
Johannesburg 52
Mexico City 51
Bremen 49
Da Nang 49
Poplar 48
Baghdad 44
Düsseldorf 44
Fairfield 44
San Francisco 44
Nanchang 42
Palermo 40
Brussels 39
Belo Horizonte 38
Rio de Janeiro 38
Shanghai 38
Lappeenranta 37
Pune 37
Redwood City 33
Ankara 32
Augusta 32
Lawrence 32
Turku 32
Brasília 31
Detroit 29
Haiphong 29
Vienna 29
Lancaster 28
Turin 28
Bologna 27
Hebei 27
Mumbai 27
Naples 27
Abidjan 26
Brno 26
Falkenstein 26
Tianjin 26
Washington 26
Biên Hòa 25
Florence 25
Manchester 25
New Delhi 25
Totale 16.863
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 1.048
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 507
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 427
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 342
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 317
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 316
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 310
Language Development in Preschool Duchenne Muscular Dystrophy Boys 306
Neurological examination of preterm infants a term equivalent age 279
Cortical visual function in preterm infants in the first year. 279
Longitudinal natural history of type I spinal muscular atrophy: A critical review 269
Performance of Upper Limb module for Duchenne muscular dystrophy 259
Prognostic value of EEG performed at term age in preterm infants. 237
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 235
Assessing floppy infants: a new module 223
-Thalamic atrophy in infants with PVL and cerebral visual impairment 213
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 207
Crossed cerebellar atrophy of prenatal onset 205
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 199
Developmental milestones in type I spinal muscular atrophy 194
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 190
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 189
A current approach to heart failure in Duchenne muscular dystrophy 188
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 184
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 184
Visual development in prenatal post-haemorragic ventricular dilatation 184
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 183
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 182
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 178
Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy 178
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 174
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 173
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 173
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 172
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 170
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 170
Muscle MRI in Becker muscular dystrophy 169
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 169
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 167
Muscle MRI in Becker muscular dystrophy 166
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 166
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 164
Muscle MRI: Out of the tunnel. 162
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 161
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 161
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 160
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 159
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 159
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 159
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 159
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 158
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 158
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis 156
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 156
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 154
Predominant distal muscle involvement in spinal muscular atrophy 153
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 153
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 152
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 151
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 150
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 150
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 149
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 149
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 149
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 149
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 149
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 148
Revised upper limb module for spinal muscular atrophy: Development of a new module 148
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 148
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 147
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 146
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 146
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 146
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 146
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 145
Longitudinal assessments in discordant twins with SMA 145
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 145
Early treatment of type II SMA slows rate of progression of scoliosis 144
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 144
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 143
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 143
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 142
Congenital muscular dystrophies with cognitive impairment. A population study 142
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 141
6 minute walk test in duchenne MD patients with different mutations:12 month changes 140
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 140
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 138
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 137
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 137
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 137
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 137
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 136
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 136
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 136
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 135
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 135
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 134
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 134
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 134
The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy 133
Totale 18.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 139.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.020 0 0 21 110 80 38 23 192 68 67 208 213
2022/20233.141 302 385 205 465 198 400 221 281 398 60 147 79
2023/20242.651 114 471 102 179 106 410 354 102 52 131 270 360
2024/20255.462 124 100 405 245 458 262 230 242 782 421 1.221 972
2025/202615.483 1.773 538 1.054 1.899 2.791 1.855 2.367 645 758 833 616 354
2026/20272.352 546 1.335 471 0 0 0 0 0 0 0 0 0
Totale 33.043